May 17, 2021 4:05 pm EDT Rezolute Reports Third Quarter Fiscal 2021 Financial Results and Highlights Recent Company Progress
May 4, 2021 8:00 am EDT Rezolute Announces Positive RZ402 Study Results Demonstrating Potential for Once Daily Dosing of an Oral Plasma Kallikrein Inhibitor for Diabetic Macular Edema
Apr 19, 2021 8:00 am EDT Rezolute Announces $30 Million Debt Financing Agreement with SLR Capital Partners
Mar 22, 2021 8:00 am EDT Rezolute Presents Data on RZ358 in Post-Gastric Bypass Hypoglycemia at ENDO 2021
Mar 8, 2021 8:00 am EST Rezolute Strengthens Board of Directors with Key Appointments of Leading Rare Disease Experts
Jan 12, 2021 8:30 am EST Rezolute Announces Initiation of Phase 1 Study of RZ402, an Oral Plasma Kallikrein Inhibitor for the Treatment of Diabetic Macular Edema
